May 29, 2024 07:26 AM EDTUpdated 03:19 PM
Deals

Bris­tol My­ers pays $80M to li­cense an­oth­er Prothena neu­ro­science can­di­date

Katherine Lewin

News Reporter

Bris­tol My­ers Squibb is shelling out $80 mil­lion to Prothena for an ex­clu­sive glob­al li­cense for an ear­ly-stage neu­rode­gen­er­a­tive can­di­date, as the phar­ma gi­ant con­tin­ues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Benev­o­len­tAI CEO is out af­ter less than a year on the job

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times